|
1
|
Duchemann B, Remon J, Naigeon M, Mezquita
L, Ferrara R, Cassard L, Jouniaux JM, Boselli L, Grivel J, Auclin
E, et al: Integrating circulating biomarkers in the immune
checkpoint inhibitor treatment in lung cancer. Cancers (Basel).
12(3625)2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Tang S, Qin C, Hu H, Liu T, He Y, Guo H,
Yan H, Zhang J, Tang S and Zhou H: Immune checkpoint inhibitors in
non-small cell lung cancer: Progress, challenges, and prospects.
Cells. 19(320)2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ding H, Xin W, Tong Y, Sun J, Xu G, Ye Z
and Rao Y: Cost effectiveness of immune checkpoint inhibitors for
treatment of non-small cell lung cancer: A systematic review. PLoS
One. 15(e0238536)2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833.
2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Signorelli D, Giannatempo P, Grazia G,
Aiello MM, Bertolini F, Mirabile A, Buti S, Vasile E, Scotti V,
Pisapia P, et al: Patients selection for immunotherapy in solid
tumors: Overcome the Naïve vision of a single biomarker. Biomed Res
Int. 2019(9056417)2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kim J, Ha H, Park J, Cho J, Lim JH and Lee
MH: Association of smoking status with efficacy of first-line
immune checkpoint inhibitors in advanced non-small cell lung
cancers: A systematic review and meta-analysis. J Cancer.
13:364–372. 2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Socinski M, Velcheti V, Mekhail T, Chae
YK, Leal TA, Dowell JE, Tsai ML, Dakhil CS, Stella P, Shen V, et
al: LBA83 - Final efficacy results from B-F1RST, a prospective
phase II trial evaluating blood-based tumour mutational burden
(bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L
non-small cell lung cancer (NSCLC). Ann Oncol. 30:v919–v920.
2019.
|
|
8
|
Mezquita L, Auclin E, Ferrara R, Charrier
M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L,
Audigier-Valette C, et al: Association of the lung immune
prognostic index with immune checkpoint inhibitor outcomes in
patients with advanced non-small cell lung cancer. JAMA Oncol.
4:351–357. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Mountzios G, Samantas E, Senghas K, Zervas
E, Krisam J, Samitas K, Bozorgmehr F, Kuon J, Agelaki S, Baka S, et
al: Association of the advanced lung cancer inflammation index
(ALI) with immune checkpoint inhibitor efficacy in patients with
advanced non-small-cell lung cancer. ESMO Open.
6(100254)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Corbeau I, Jacot W and Guiu S: Neutrophil
to lymphocyte ratio as prognostic and predictive factor in breast
cancer patients: A systematic review. Cancers (Basel).
12(958)2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Li Y, Zhang Z, Hu Y, Yan X, Song Q, Wang
G, Chen R, Jiao S and Wang J: Pretreatment neutrophil-to-lymphocyte
ratio (NLR) may predict the outcomes of advanced non-small-cell
lung cancer (NSCLC) patients treated with immune checkpoint
inhibitors (ICIs). Front Oncol. 10(654)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Diem S, Schmid S, Krapf M, Flatz L, Born
D, Jochum W, Templeton AJ and Früh M: Neutrophil-to-Lymphocyte
ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic
markers in patients with non-small cell lung cancer (NSCLC) treated
with nivolumab. Lung Cancer. 111:176–181. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Banna GL, Cortellini A, Cortinovis DL,
Tiseo M, Aerts JGJV, Barbieri F, Giusti R, Bria E, Grossi F,
Pizzutilo P, et al: The lung immuno-oncology prognostic score
(LIPS-3): A prognostic classification of patients receiving
first-line pembrolizumab for PD-L1 ≥50% advanced non-small-cell
lung cancer. ESMO Open. 6(100078)2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The eighth edition AJCC cancer staging manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J. 67:93–99.
2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Seymour L, Bogaerts J, Perrone A, Ford R,
Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, et
al: iRECIST: Guidelines for response criteria for use in trials
testing immunotherapeutics. Lancet Oncol. 18:e143–e152.
2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
US Department of Health and Human
Services. Common Terminology Criteria for Adverse Events (CTCAE)
Version 5. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf.
|
|
17
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus Docetaxel in advanced Nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Mazieres J, Rittmeyer A, Gadgeel S, Hida
T, Gandara DR, Cortinovis DL, Barlesi F, Yu W, Matheny C, Ballinger
M and Park K: Atezolizumab Versus docetaxel in pretreated patients
with NSCLC: Final results from the randomized phase 2 POPLAR and
phase 3 OAK clinical trials. J Thorac Oncol. 16:140–150.
2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kim J, Cho J, Lee MH and Lim JH: Relative
efficacy of checkpoint inhibitors for advanced NSCLC according to
programmed death-ligand-1 expression: A systematic review and
network meta-analysis. Sci Rep. 8(11738)2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Prelaj A, Rebuzzi SE, Pizzutilo P,
Bilancia M, Montrone M, Pesola F, Longo V, Del Bene G, Lapadula V,
Cassano F, et al: EPSILoN: A prognostic score using clinical and
blood biomarkers in advanced non-small-cell lung cancer treated
with immunotherapy. Clin Lung Cancer. 21:365–377.e5.
2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Rounis K, Makrakis D, Papadaki C,
Monastirioti A, Vamvakas L, Kalbakis K, Gourlia K, Xanthopoulos I,
Tsamardinos I, Mavroudis D and Agelaki S: Prediction of outcome in
patients with non-small cell lung cancer treated with second line
PD-1/PDL-1 inhibitors based on clinical parameters: Results from a
prospective, single institution study. PLoS One.
16(e0252537)2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Maugeais M, Péron J, Dalle S, Boespflug A,
Duruissaux M, Corbaux P, Reverdy T, Sahin G, Rabier A, Lopez J, et
al: Impact of liver metastases and number of metastatic sites on
immune-checkpoint inhibitors efficacy in patients with different
solid tumors: A retrospective study. Biomedicines.
29(83)2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Xia H, Zhang W, Zhang Y, Shang X, Liu Y
and Wang X: Liver metastases and the efficacy of immune checkpoint
inhibitors in advanced lung cancer: A systematic review and
meta-analysis. Front Oncol. 12(978069)2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Vaddepally R, Doddamani R, Sodavarapu S,
Madam NR, Katkar R, Kutadi AP, Mathew N, Garje R and Chandra AB:
Review of immune-related adverse events (irAEs) in non-small-cell
lung cancer (NSCLC)-their incidence, management, multiorgan irAEs,
and rechallenge. Biomedicines. 10(790)2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Grangeon M, Tomasini P, Chaleat S, Jeanson
A, Souquet-Bressand M, Khobta N, Bermudez J, Trigui Y, Greillier L,
Blanchon M, et al: Association between immune-related adverse
events and efficacy of immune checkpoint inhibitors in
non-small-cell lung cancer. Clin Lung Cancer. 20:201–207.
2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Okada N, Kawazoe H, Takechi K, Matsudate
Y, Utsunomiya R, Zamami Y, Goda M, Imanishi M, Chuma M, Hidaka N,
et al: Association between immune-related adverse events and
clinical efficacy in patients with melanoma treated with Nivolumab:
A multicenter retrospective study. Clin Ther. 41:59–67.
2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Gärtner F, Aßmus J, Fløtten Ø, Ramnefjell
MP and Aanerud M: Characteristics and survival of patients with
non-small cell lung cancer treated with immune-checkpoint
inhibitors in the real-world: Experiences from Bergen, Norway. Acta
Oncol (Madr). 61:814–818. 2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Takeuchi E, Kondo K, Okano Y, Kunishige M,
Kondo Y, Kadota N, Machida H, Hatakeyama N, Naruse K, Ogino H, et
al: Early mortality factors in immune checkpoint inhibitor
monotherapy for advanced or metastatic non-small cell lung cancer.
J Cancer Res Clin Oncol. 149:3139–3147. 2023.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Corke LK, Li JJN, Leighl NB and Eng L:
Tobacco use and response to immune checkpoint inhibitor therapy in
non-small cell lung cancer. Curr Oncol. 29:6260–6276.
2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Zhao W, Jiang W, Wang H, He J, Su C and Yu
Q: Impact of smoking history on response to immunotherapy in
non-small-cell lung cancer: A systematic review and meta-analysis.
Front Oncol. 11(703143)2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Wang X, Ricciuti B, Alessi JV, Nguyen T,
Awad MM, Lin X, Johnson BE and Christiani DC: Smoking history as a
potential predictor of immune checkpoint inhibitor efficacy in
metastatic non-small cell lung cancer. J Natl Cancer Inst.
113:1761–1769. 2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Popat S, Liu SV, Scheuer N, Gupta A, Hsu
GG, Ramagopalan SV, Griesinger F and Subbiah V: Association between
smoking history and overall survival in patients receiving
Pembrolizumab for first-line treatment of advanced non-small cell
lung cancer. JAMA Netw Open. 5(e2214046)2022.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Cedrés S, Torrejon D, Martínez A, Martinez
P, Navarro A, Zamora E, Mulet-Margalef N and Felip E: Neutrophil to
lymphocyte ratio (NLR) as an indicator of poor prognosis in stage
IV non-small cell lung cancer. Clin Transl Oncol. 14:864–869.
2012.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Raskov H, Orhan A, Gaggar S and Gögenur I:
Neutrophils and polymorphonuclear myeloid-derived suppressor cells:
An emerging battleground in cancer therapy. Oncogenesis.
11(22)2022.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Peng B, Wang YH, Liu YM and Ma LX:
Prognostic significance of the neutrophil to lymphocyte ratio in
patients with non-small cell lung cancer: A systemic review and
meta-analysis. Int J Clin Exp Med. 8:3098–3106. 2015.PubMed/NCBI
|
|
36
|
Cao D, Xu H, Xu X, Guo T and Ge W: A
reliable and feasible way to predict the benefits of Nivolumab in
patients with non-small cell lung cancer: A pooled analysis of 14
retrospective studies. Oncoimmunology. 7(e1507262)2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Suh KJ, Kim SH, Kim YJ, Kim M, Keam B, Kim
TM, Kim DW, Heo DS and Lee JS: Post-treatment
neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients
with advanced non-small cell lung cancers treated with anti-PD-1
antibody. Cancer Immunol Immunother. 67:459–470. 2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Lim JU, Kang HS, Yeo CD, Kim JS, Park CK,
Kim JW, Kim SJ and Lee SH: Predictability of early changes in
derived neutrophil-to-lymphocyte ratio and neutrophil-to-lymphocyte
ratio in patients with advanced non-small cell lung cancer treated
with immune checkpoint inhibitors. J Thorac Dis. 13:2824–2832.
2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Simonelli M, Calvo E, Davar D, Richards D,
Gutierrez M, Garcia VM, Marron T, Rottey S, Orcurto A, Renouf DJ,
et al: 200MO Anti-IL-8 BMS-986253 + nivolumab (NIVO) ± ipilimumab
(IPI) in patients (pts) with advanced cancer: Update of initial
phase I results. Immuno-Oncology and Technology.
16(100311)2022.
|
|
40
|
Barlesi F, Isambert N, Felip E, Cho BC,
Lee DH, Peguero J, Jerusalem G, Penel N, Saada-Bouzid E, Garrido P,
et al: Bintrafusp Alfa, a Bifunctional fusion protein targeting
TGF-β and PD-L1, in patients with non-small cell lung cancer
resistant or refractory to immune checkpoint inhibitors.
Oncologist. 28:258–267. 2023.
|
|
41
|
Nadal E, Saleh M, Aix SP, Ochoa-de-Olza M,
Patel SP, Antonia S, Zhao Y, Gueorguieva I, Man M, Estrem ST, et
al: A phase Ib/II study of galunisertib in combination with
nivolumab in solid tumors and non-small cell lung cancer. BMC
Cancer. 23(708)2023.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Park W, Mezquita L, Okabe N, Chae YK, Kwon
D, Saravia D, Auclin E, Planchard D, Caramella C, Ferrara R, et al:
Association of the prognostic model iSEND with PD-1/L1 monotherapy
outcome in non-small-cell lung cancer. Br J Cancer. 122:340–347.
2020.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Valero C, Lee M, Hoen D, Weiss K, Kelly
DW, Adusumilli PS, Paik PK, Plitas G, Ladanyi M, Postow MA, et al:
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden
as biomarkers of tumor response to immune checkpoint inhibitors.
Nat Commun. 12(729)2021.PubMed/NCBI View Article : Google Scholar
|
